On December 18, 2025, President Trump signed a groundbreaking Executive Order titled "Increasing Medical Marijuana and Cannabidiol Research." The policy may accelerate U.S. research by easing restrictions, enabling more institutions to study CBD, and potentially strengthening the evidence base that informs safety, quality, and usage education for topical applications. Information is educational and not medical advice.
For Indigo Wellness, the policy highlights a commitment to 0% THC CBD topicals, rigorous third‑party testing, and transparent quality standards—while creating potential opportunities to collaborate on studies that could inform safer formulations, clearer usage education, and stronger quality benchmarks. Products are not intended to diagnose, treat, cure, or prevent any disease; experiences vary.
What Changed for CBD Research Access
The Executive Order directs federal agencies to expedite marijuana's rescheduling from Schedule I to Schedule III, potentially removing significant regulatory barriers that have limited comprehensive CBD research for decades. Under Schedule I classification, researchers faced extensive bureaucratic hurdles, limited institutional participation, and restricted access to standardized materials for studies.
Key research improvements include:
• Expanded institutional participation – More universities and research centers may now conduct CBD studies
• Streamlined regulatory processes – Reduced DEA constraints on research protocols
• Enhanced federal research infrastructure across HHS, FDA, CMS, and NIH
• Real-world evidence models using actual patient data rather than solely traditional clinical trials
This shift particularly benefits topical CBD product research, as these formulations often require specialized dermatological and pain management studies that were previously difficult to conduct under restrictive scheduling. For Indigo Wellness, expanded access may enable participation in collaborative studies and real‑world evidence projects that align with the brand’s safety-first approach and educational mission.
Specific Impact on THC-Free Topical CBD Products
Companies like Indigo Wellness that focus on 0% THC topical formulations may see significant advantages from expanded research access. Current studies exploring CBD's interaction with the endocannabinoid system have been limited by regulatory constraints, but increased research opportunities could provide more comprehensive data on how cannabidiol may interact with skin receptors and localized pain pathways. Indigo Wellness maintains a 0% THC policy for topicals verified via independent third‑party testing and applies those results to transparent quality standards across batches; individuals seeking product details can review Certificates of Analysis before considering options like the 3000mg CBD Pain Cream.
Research areas that may expand include:
• Dermatological absorption studies – How different CBD concentrations penetrate skin barriers
• Localized experience research – Potential sensations of targeted comfort and wellness experiences
• Safety profile development – Long-term skin sensitivity and tolerance studies
• Formulation optimization – Enhanced delivery mechanisms for topical applications
| Policy-enabled research focus | Potential Indigo Wellness action |
|---|---|
| Dermatological absorption | Support or learn from independent absorption studies; apply findings to label guidance and formulation adjustments |
| Localized experience outcomes | Participate in real‑world evidence projects that may explore sensations of comfort in targeted areas |
| Long-term safety/tolerance | Maintain ongoing third‑party testing, document skin sensitivity feedback, and refine QA protocols |
| Delivery mechanism optimization | Evaluate research on emulsions and carriers to inform consistent, 0% THC topical formulations |
Table is illustrative; research is ongoing and outcomes are not guaranteed.
Current research remains limited, and experiences may vary significantly between individuals.
Enhanced Safety and Quality Standards
Increased research access may lead to more rigorous safety protocols and quality standards for THC-free CBD products. The Executive Order directs agencies to develop standardized research methods that could address current industry challenges including inconsistent product labeling, quality variability, and lack of standardized clinical guidance.
Potential safety improvements:
• Standardized testing protocols for verifying 0% THC claims
• Enhanced contaminant screening for pesticides, heavy metals, and residual solvents
• Improved batch consistency through research-backed manufacturing processes
• Better understanding of interaction profiles with other wellness ingredients
Companies maintaining rigorous third-party testing standards may benefit from research that validates their quality assurance approaches and potentially establishes industry-wide benchmarks. For Indigo Wellness, this aligns with existing practices:
• Publicly accessible Certificates of Analysis (COAs) for each batch
• Verification of 0% THC in topicals through ISO-accredited laboratories
• Transparent sourcing and manufacturing disclosures, with continuous QA reviews
• Clear labeling and cautious, FDA-compliant education resources
Product Development and Innovation Opportunities
The policy changes may accelerate innovation in topical CBD formulations by providing researchers with better access to study various cannabinoid profiles, delivery mechanisms, and synergistic botanical combinations. For Indigo Wellness, this could inform how CBD isolate interacts with moisturizing butters (shea, cocoa, mango) and aromatics like Frankincense, while maintaining 0% THC and prioritizing safety and transparency.
Areas of potential innovation:
• Advanced delivery systems – Research into nano-emulsions, liposomes, and transdermal technologies
• Botanical synergies – Studies exploring how CBD may work with other plant compounds
• Targeted formulations – Products designed for specific wellness applications based on research findings
• Personalized wellness – Research supporting customized CBD approaches for individual needs
These developments are speculative and depend on ongoing research outcomes. Products are not intended to diagnose, treat, cure, or prevent any disease. Individuals interested in THC-free options may review Indigo Wellness’s 3000mg CBD Pain Cream and testing results; experiences vary and personal preference plays a role.
Timeline and Regulatory Considerations
While the Executive Order signals significant federal policy shifts, implementation may occur gradually through 2026 and beyond. Several key deadlines may impact the CBD industry:
Critical timeline milestones:
• February 2026 – FDA must publish updated cannabinoid definitions
• November 2026 – New statutory THC thresholds become enforceable
• Ongoing – Congressional action needed for comprehensive cannabis reform
The order represents federal acknowledgment of cannabis's potential medical value but still requires coordination between agencies and congressional support to fully translate research opportunities into accessible, standardized products (see the official Executive Order: https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/). For authoritative updates and definitions as they evolve, refer to the FDA’s overview of cannabis and CBD regulation (https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd) and NIH/NCCIH background on cannabinoids and research status (https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know).
What This Means for Wellness-Focused Consumers
Individuals interested in topical CBD for comfort and wellness may benefit from enhanced research that could provide clearer guidance on product selection, usage protocols, and safety considerations. However, the immediate impact may be limited as research studies typically require years to complete and publish findings.
Potential long-term benefits:
• Better product standardization across the industry
• Improved safety data for topical CBD applications
• Enhanced quality assurance protocols
• Clearer usage guidelines based on research evidence
Current products remain subject to existing regulations, and individuals should consult healthcare providers before starting any new wellness routine.
Industry Standards and Quality Assurance
The research expansion may lead to more sophisticated industry standards for THC-free CBD products. Companies that have already invested in rigorous quality control, comprehensive testing, and transparent manufacturing processes may find their approaches validated by emerging research standards.
Quality factors that research may validate:
• CO2 extraction methods for maintaining cannabinoid integrity
• Third-party testing protocols for ensuring product purity
• Storage and stability studies for maintaining product potency
• Formulation compatibility with other wellness ingredients
Research is ongoing, and current quality standards may evolve as scientific understanding advances.
Indigo Wellness: Testing, Transparency, and Education
Indigo Wellness remains committed to rigorous third-party verification, 0% THC CBD topicals, and transparent quality standards. Expanded research access may support collaborations that help validate safety protocols and inform clearer guidance, while maintaining a balanced, FDA-compliant approach to education.
Key commitments and next steps:
• Maintain public COAs and independent testing for 0% THC topicals
• Participate in or learn from dermatological absorption and real‑world evidence studies as they become available
• Translate emerging evidence into plain-language resources, building on guides like CBD and pain: what to know and CBD and the endocannabinoid system
• Apply findings to optimize botanical-forward formulations (e.g., CBD isolate with shea, cocoa, mango butters and Frankincense), prioritizing safety, consistency, and 0% THC
Education is informational and not medical advice; products are not intended to diagnose, treat, cure, or prevent any disease. Experiences vary and depend on individual factors.
Individuals interested in THC-free topicals can browse options like the 3000mg CBD Pain Cream and review COAs prior to purchase decisions.
Looking Forward: Research and Development
The Executive Order may catalyze a new era of evidence-based CBD product development, particularly for companies focused on THC-free formulations. As research infrastructure expands, consumers may gain access to products backed by more comprehensive scientific data regarding safety, effectiveness, and optimal usage protocols.
Future research priorities may include:
• Long-term safety studies for regular topical CBD use
• Effectiveness comparisons between different CBD formulations
• Interaction studies with medications and other supplements
• Population-specific research for different age groups and health conditions
These research areas are speculative and depend on funding, regulatory approval, and scientific interest. Results may take years to publish and implement.
The policy changes represent a significant step toward evidence-based CBD wellness products, though the full impact may not be realized for several years as research studies progress through development, approval, and publication phases. Those interested in THC‑free topicals may browse Indigo Wellness’s selection or continue learning through the linked resources above; experiences vary and personal preference plays a role.
